Table 1.
Baseline demographics for the cohort and by treatment group.
| All (N=22) Median (Q1, Q3) n (%) |
Placebo (N=11) Median (Q1, Q3) n (%) |
Rosuvastatin (N=11) Median (Q1, Q3) n (%) |
|
|---|---|---|---|
|
| |||
| Age (years) | 50.3 (47.1, 53.2) | 49.2 (48.5, 52.9) | 51.3 (45, 54.4) |
| Female, n (%) | 7 (31.8) | 3 (27.3) | 4 (36.4) |
| African-American, n (%) | 12 (54.5) | 6 (54.5) | 6 (54.5) |
| Hispanic, n (%) | 1 (4.5) | 1 (9.1) | 0 (0) |
| Body mass index (kg/m2) | 24.5 (20.9, 27.6) | 25.7 (21.3, 26.6) | 21.7 (20.6, 27.9) |
| Ever smoked cigarettes, n (%) | 19 (86.4) | 10 (90.9) | 9 (81.8) |
| Total pack years smoked | 12.1 (4.8, 27.4) | 11.7 (10, 20.9) | 13 (4, 27.1) |
| CD4 cell count (cells/μl) | 630 (526, 784) | 660 (539.5, 866) | 624 (505.5, 756.5) |
| HIV viral level < 40 copies/ml, n (%) | 17 (77.3) | 9 (81.8) | 8 (72.7) |
| ART use, n (%) | 21 (95.5) | 11 (100) | 10 (90.9) |
| hs-CRP (mg/l) | 0.27 (0.13, 0.6) | 0.18 (0.1, 0.37) | 0.40 (0.17, 1.07) |
| Total cholesterol (mg/dl) | 164 (148, 204.3) | 160 (144.5, 175.5) | 176 (157.5, 209) |
| HDL (mg/dl) | 45 (36.3, 66.5) | 41 (36.5, 58.5) | 47 (36.5, 72.5) |
| Total cholesterol/HDL | 3.7 (2.5, 4.8) | 3.7 (3.4, 4.2) | 4.7 (2.2, 5.2) |
| LDL (mg/dl) | 89 (69, 105) | 89 (81, 98.5) | 101.5 (69, 133.5) |
Abbreviations: ART, antiretroviral therapy; hs-CRP, high sensitivity C-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; SD, standard deviation; Q, quartile.